New NCCN Resources for Non-Hodgkin's Lymphomas Empower Patients to Make Informed Treatment Decisions

FORT WASHINGTON, PA—(Marketwired – April 28, 2016) – It is estimated that more than 72,000 people in the United States will be diagnosed with Non–Hodgkin's Lymphomas (NHL) in 2016[1]. The sixth leading cancer diagnosis in U.S. men and women[2], NHL has more than 30 sub–types, each featuring unique treatment choices and challenges.[3]

To further educate people with Non–Hodgkin's Lymphomas (NHL) and empower them to make informed treatment decisions for their disease, the National Comprehensive Cancer Network® (NCCN®), through support of the NCCN Foundation®, has published NCCN Guidelines for Patients® and NCCN Quick Guide™ series for NHL, specifically for Diffuse Large B–Cell, Follicular, Mantle Cell, and Peripheral T–Cell Lymphoma. The NCCN Guidelines for Patients®: Diffuse Large B–Cell Lymphoma and Follicular Lymphoma are made possible, in part, through generous sponsorship from The Leukemia & Lymphoma Society.

These patient reference booklets are part of a larger series of patient education materials for Non–Hodgkin's Lymphomas that also includes Chronic Lymphocytic Leukemia, which was published earlier this year. NCCN Guidelines for Patients® for Mycosis Fungoides is also expected to publish soon.

“The goal of the NCCN Foundation is to deliver true insight to people living with the challenges and complexities of a cancer diagnosis so they can take an active role in their care and the care of their loved ones,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “We are proud to collaborate with The Leukemia & Lymphoma Society to make these resources available for people with Non–Hodgkin's Lymphomas.”

NCCN Guidelines for Patients, translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), are designed to provide people with cancer and their caregivers with state–of–the–art treatment information in easy–to–understand language. The NCCN Guidelines® are developed by multidisciplinary, volunteer panels of experts from the NCCN Member Institutions and feature algorithms that address appropriate management options from initial work–up through the course of the disease.

NCCN Guidelines for Patients and the NCCN Quick Guide™ series, abbreviated references outlining key points of the NCCN Guidelines for Patients, are written according to plain language principles to improve health literacy with clean design and formats featuring patient–friendly elements, such as medical illustrations of anatomy, tests, and treatments. These resources also feature an expansive glossary of terms and acronyms. The NCCN Guidelines for Patients and the NCCN Quick Guide™ series do not replace the expertise and clinical judgment of the physician.

NCCN currently offers NCCN Guidelines for Patients for the following: Breast, Colon, Esophageal, Kidney, Non–Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Acute Lymphoblastic Leukemia (ALL); Caring for Adolescents and Young Adults (AYA); Chronic Myelogenous Leukemia (CML); Hodgkin Lymphoma, Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; NHL; and Soft Tissue Sarcoma.

To download for free or order the NCCN Guidelines for Patients and NCCN Quick Guide™ series for NHL, visit NCCN.org/patients.

About NCCN Foundation

Through philanthropy, the NCCN Foundation® empowers people through knowledge and advances the mission of NCCN to improve the quality, effectiveness, and efficiency of cancer care, so that patients can live better lives. Visit NCCNFoundation.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not–for–profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high–quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision–makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana–Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes–Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt–Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.

[1] “Cancer Facts & Figures 2016.” American Cancer Society. Web. 28 Apr. 2016.

[2] “Cancer Facts & Figures 2016.” American Cancer Society. Web. 28 Apr. 2016.

[3] “Non–Hodgkin Lymphoma.” The Leukemia & Lymphoma Society. 27 Apr. 2016.

The following files are available for download:

Hagens Berman Reminds TerraForm Power, Inc. (NASDAQ: TERP) Investors of June 3, 2016 Lead Plaintiff Deadline in Deficient-Internal-Control-Related Securities Class Action

SAN FRANCISCO, CA—(Marketwired – April 28, 2016) –
 Hagens Berman Sobol Shapiro LLP, a national investor–rights law firm, reminds TerraForm Power, Inc. (NASDAQ: TERP) investors of the June 3, 2016 lead plaintiff deadline in the securities class action lawsuit related to defendants' alleged false and misleading statements and/or failures to disclose the ineffectiveness of TerraForm Power's internal controls.

If you suffered significant losses because of your purchases of TerraForm Power stock between May 7, 2015 and March 15, 2016 or have information that will help our investigation contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation by calling 510–725–3000, emailing TERP@hbsslaw.com or visiting https://www.hbsslaw.com/cases/TERP. The lawsuit was filed in the U.S. District Court for the District of Maryland, Greenbelt Division and investors have until June 3, 2016 to move the court to participate as a lead plaintiff.

The complaint alleges that on February 29, 2016, SunEdison (TerraForm's controlling shareholder) announced that it would not timely file its 2015 Form 10–K, due to the fact it was investigating allegations that its financial statements were inaccurate.

The same day, TerraForm similarly announced it would not timely file its 2015 Form 10–K, but only vaguely explained it had not finalized its financial statements and disclosures.

On March 16, 2016, SunEdison disclosed its management identified material internal control weaknesses. 

The same day, TerraForm announced that SunEdison's material control weaknesses required it “to assess whether those deficiencies could affect our financial reporting[.]” On this news, TerraForm stock fell $0.83, or 7.87%, to close at $9.72 on March 16, 2016.

“Strong internal controls are critical toward ensuring against employee misconduct and financial statement accuracy, and TerraForm's outsourcing of that function to its controlling shareholder has damaged its shareholders,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non–public information regarding TerraForm Power, Inc. should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510–725–3000
or email TERP@hbsslaw.com. 

About Hagens Berman

Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm's Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.